← Drug database

Pyzchiva (ustekinumab)

BiosimilarAdditional monitoring
Region
🇪🇺 EU
Active substance
ustekinumab
Company
Samsung Bioepis NL B.V.
Status
Authorised
Therapeutic area
Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
CHMP opinion
Thu 22 Feb 2024
EU approval
Fri 19 Apr 2024
Designations
Biosimilar, Additional monitoring
Application
EMEA/H/C/006183
ATC
L04AC05
Official record
www.ema.europa.eu

Indication

Crohn’s DiseasePyzchiva is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Plaque psoriasisPyzchiva is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1).Paediatric plaque psoriasisPyzchiva is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1). Psoriatic arthritis (PsA)Pyzchiva, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1).

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Pyzchiva

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.